Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical

SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company …